A review on the history, use, and new developments of abobotulinumtoxinA (Dysport)

Abstract

AbobotulinumtoxinA is a botulinum neurotoxin type A that blocks the release of acetylcholine from peripheral cholinergic nerve terminals and thereby induces flaccid paralysis. It is the second produced botulinum neurotoxin type A of its class and is currently approved for the use in spasticity, dystonia in adults, and correction of glabellar wrinkle lines in adults up to 65 years of age. Though these are the only US Food and Drug Administration (FDA) indications for its use, there are many off-label uses for abobotulinumtoxinA such as various facial lines, hyperhidrosis, temporomandibular disease, and other neuromuscular conditions. This summary article reviews the history, development, unique properties, clinical indications, and safety profile of abobotulinumtoxinA.

Efficacy and Safety of AbobotulinumtoxinA for Treatment of Moderate-to-Severe Glabellar Lines: A Meta-Analysis

“…ABO has been widely used to treat cervical dystonia, limb spasticity, and other neuromuscular disorders, and has shown good safety and efficacy. [7][8][9] In recent years, ABO has also been used to treat glabellar lines and other facial wrinkles, and has achieved satisfactory results. [10][11][12] ABO can act directly on the glabellar muscles by injection, making them relax and smoothing glabellar lines, while maintaining the naturalness of facial expressions.…”